Crenezumab
Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune, which licensed the drug in 2006 to Genentech, Inc. Its original name RG7412 refers to its inventor at AC Immune. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides.